IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
Molecular testing, or molecular diagnostics, refers to a group of tests that look at the genetic material in a specimen. It can detect genetic risk factors for certain diseases or provide evidence of ...
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, driven by expanding precision medicine adoption and advanced genetic testing. North America leads the market, ...
cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...
SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...
Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Accelerating Market Expansion Globally.Austin, United States, March 09, 2026 (GLOBE NEWSWIRE) -- Point-of-Care ...
Dipylon Medical Expands Access to Clinical Microbiology Equipment for Modern Diagnostic Laboratories
Expanding access to advanced PCR thermocyclers, DNA & RNA purification systems, and hematology analyzers for modern clinical laboratories SINGAPORE, SG / ACCESS Newswire / March 7, 2026 / Dipylon ...
December 2024 was declared a "high severity" flu season by the Centre for Disease Control (CDC), the worst in over half a decade. Hospitalization rates were up to 2.8 times higher than the median ...
"We're thrilled to partner with Molecular Lab Partners to bring rapid, scalable solutions to POLs and urgent care labs nationwide. Together, we're helping to advance diagnostics by making operations ...
As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a ...
New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNARei ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results